

Notes to Editors

Morphotek's Pipeline:

Clinical Stage	Product Name/Code	Description/Mode of Action	Target Disease
Phase I/II	MORAb-003	Humanized IgG1 antibody	Ovarian cancer
Phase I	MORAb-009	IgG1 antibody	Pancreatic/ Lung cancer
Preclinical (IND preparation)	MORAb-004	Humanized IgG1 antibody	Melanoma/ Neovascular disease
Preclinical (IND preparation)	MORAb-022	Fully human IgG1 monoclonal antibody	Autoimmune diseases
Preclinical	MORAb-028	Fully human IgM monoclonal antibody	Metastatic melanoma
Preclinical	MORAb-047	Therapeutic antibody	Infectious disease
Preclinical	MORAb-048	Therapeutic antibody	Infectious disease

Eisai's Oncology Pipeline:

Clinical Stage	Product Name/Code	Description/Mode of Action	Target Cancer
Preparing for Subpart H submission	E7389	Microtubule growth suppressor	Breast, Non-small Cell Lung, Prostate, Ovarian, Sarcoma
Phase I	E7070	Cell cycle G1 phase targeting agent	Small Cell Lung
Phase I	E7820	Anti-angiogenesis agent	Various
Phase I	E7080	Anti-angiogenesis agent	Various
Phase I	E7974	Hemiasterlin type tubulin polymerization inhibitor	Various
Phase I in preparation	E7107	Anti-tumor agent derived from fermentation	Various

Major Technology Platform of Morphotek:

Fully-human monoclonal antibody generation and optimization (Human MORPHODOMA[®], Libradoma[™])

About Human MORPHODOMA[®]

Human MORPHODOMA[®] is able to generate fully human monoclonal antibodies. Furthermore, through the application of its proprietary technology and know-how, Morphotek is able to optimize the titer of its cell-lines, effect class switching, and enhance antibody affinity.

About Libradoma[™]

The Libradoma[™] technology process utilizes Human MORPHODOMA[®] and other propriety technologies to generate libraries potentially comprised of thousands of hybridomas that can be rapidly screened using high-throughput robotics to identify hybridomas expressing human antibodies with target affinity profiles.